

Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Pipeline Review, H1 2018

<https://marketpublishers.com/r/PC5827AA608EN.html>

Date: June 2018

Pages: 64

Price: US\$ 3,500.00 (Single User License)

ID: PC5827AA608EN

Abstracts

Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Pipeline Review, H1 2018

SUMMARY

According to the recently published report 'Prostate Specific Antigen - Pipeline Review, H1 2018'; Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) pipeline Target constitutes close to 12 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes.

Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Prostate-specific antigen (PSA) is a glycoprotein enzyme encoded by the KLK3 gene. PSA is secreted by the epithelial cells of the prostate gland. It hydrolyzes semenogelin-1 this leads to the liquefaction of the seminal coagulum.

The report 'Prostate Specific Antigen - Pipeline Review, H1 2018' outlays comprehensive information on the Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Prostate Specific Antigen (Gamma

Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, IND/CTA Filed and Preclinical stages are 2, 2, 1 and 4 respectively.

Similarly, the universities portfolio in Phase II stages comprises 3 molecules, respectively. Report covers products from therapy areas Oncology which include indications Prostate Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Hormone Refractory (Castration Resistant and Androgen-Independent) Prostate Cancer.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77)

The report reviews Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) targeted therapeutics and enlists all their major and minor projects

The report assesses Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) targeted

therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Overview

Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Companies Involved in Therapeutics Development

Advaxis Inc

Bavarian Nordic A/S

Inovio Pharmaceuticals Inc

Inspyr Therapeutics Inc

NantKwest Inc

OncBioMune Pharmaceuticals Inc

OncBioMune Pharmaceuticals Inc

Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Drug Profiles

ADX-PSA - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy to Target PSA for Prostate Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy to Target PSA, PAP, Survivin and hTERT for Metastatic Hormone Refractory Prostate Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

G-114 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

G-115 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INO-5150 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody 1 to Inhibit PSA for Prostate Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit PSA for Prostate Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Prostatac - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rilimogene galvacirepvec - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for Castration Resistant Prostate Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target Prostate Specific Antigen for Metastatic Hormone Refractory Prostate Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Dormant Products

Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Discontinued Products

Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Product Development Milestones

Featured News & Press Releases

Jun 01, 2018: Data Highlighting Advaxis' ADXS-PSA Presented at ASCO Annual Meeting

May 17, 2018: Inovio Pharmaceuticals Demonstrates PSA Stabilizing Effect of INO-5150 Immunotherapy in Phase 1b Study for Prostate Cancer

Apr 02, 2018: Data Highlighting Advaxis ADXS-PSA Accepted as Poster Presentation at the American Society of Clinical Oncology Annual Meeting

Mar 28, 2018: OncBioMune Returns Protocol to Scientific Review Committee Overseeing Phase 2 Prostate Cancer Clinical Trial

Mar 22, 2018: Scientific Review Committee Meets on OncBioMune's Phase 2 Prostate Cancer Clinical Trial

Mar 08, 2018: OncBioMune Selects Theradex as CRO for Two Phase 2 Trials of Proscavax for Prostate Cancer

Feb 28, 2018: OncBioMune Submits Phase 2 Protocol to Urology Centers of North Texas

Feb 26, 2018: OncBioMune Provides Updates on two Phase 2 Clinical Trials of Proscavax for Prostate Cancer

Feb 16, 2018: OncBioMune Provides Update on Market Activity

Feb 05, 2018: OncBioMune Signs Letter of Intent to Initiate Phase 2 Trial of Proscavax for Advanced Prostate Cancer with Urology Clinics of North Texas

Jan 10, 2018: 70% of Advanced Prostate Cancer Patients Treated with Proscavax Demonstrate Improvement in PSA Doubling Time

Dec 21, 2017: One-Year Follow-Up Shows 71.4% Progression-Free Survival in 14 Prostate Cancer Patients Treated with Proscavax in Phase 1 Clinical Trial

Dec 05, 2017: 100% of Prostate Cancer Patients Completing 31-Week Post-Therapy Exam After Treatment with OncBioMune Immunotherapy Show No Disease Progression

Nov 13, 2017: 80% of Prostate Cancer Patients in OncBioMune Phase 1 Clinical Trial of Proscavax Show No Disease Progression at the First Post-Therapy Follow-up

Sep 19, 2017: Two Abstracts Featuring Advaxis' Lm-based Candidates Selected for Presentation at the 32nd Annual Society for Immunotherapy Cancer Meeting

Appendix

Methodology

[Coverage](#)
[Secondary Research](#)
[Primary Research](#)
[Expert Panel Validation](#)
[Contact Us](#)
[Disclaimer](#)

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indication, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Advaxis Inc, H1 2018
Pipeline by Bavarian Nordic A/S, H1 2018
Pipeline by Inovio Pharmaceuticals Inc, H1 2018
Pipeline by Inspyr Therapeutics Inc, H1 2018
Pipeline by NantKwest Inc, H1 2018
Pipeline by OncBioMune Pharmaceuticals Inc, H1 2018
Dormant Projects, H1 2018
Discontinued Products, H1 2018

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018

COMPANIES MENTIONED

Advaxis Inc

Bavarian Nordic A/S

Inovio Pharmaceuticals Inc

Inspyr Therapeutics Inc

NantKwest Inc

OncBioMune Pharmaceuticals Inc

I would like to order

Product name: Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Pipeline Review, H1 2018

Product link: <https://marketpublishers.com/r/PC5827AA608EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/PC5827AA608EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

